These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26538066)

  • 1. Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility.
    Piccolo SR; Andrulis IL; Cohen AL; Conner T; Moos PJ; Spira AE; Buys SS; Johnson WE; Bild AH
    BMC Med Genomics; 2015 Nov; 8():72. PubMed ID: 26538066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility.
    Piccolo SR; Hoffman LM; Conner T; Shrestha G; Cohen AL; Marks JR; Neumayer LA; Agarwal CA; Beckerle MC; Andrulis IL; Spira AE; Moos PJ; Buys SS; Johnson WE; Bild AH
    Mol Syst Biol; 2016 Mar; 12(3):860. PubMed ID: 26969729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of germline mutations in breast cancer genes: RECQL.
    Bowden AR; Tischkowitz M
    Breast Cancer Res Treat; 2019 Apr; 174(3):553-560. PubMed ID: 30610487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic mastectomy for the prevention of breast cancer.
    Lostumbo L; Carbine N; Wallace J; Ezzo J
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002748. PubMed ID: 15495033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer.
    Guénard F; Labrie Y; Ouellette G; Beauparlant CJ; Durocher F;
    J Hum Genet; 2009 Mar; 54(3):152-61. PubMed ID: 19197335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio.
    Balmaña J; Sanz J; Bonfill X; Casado A; Rué M; Gich I; Díez O; Sabaté JM; Baiget M; Alonso MC
    Int J Cancer; 2004 Nov; 112(4):647-52. PubMed ID: 15382046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
    Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
    PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
    Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients.
    Lee E; McKean-Cowdin R; Ma H; Chen Z; Van Den Berg D; Henderson BE; Bernstein L; Ursin G
    Breast Cancer Res; 2008; 10(1):R19. PubMed ID: 18284688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating factor analysis and a transgenic mouse model to reveal a peripheral blood predictor of breast tumors.
    LaBreche HG; Nevins JR; Huang E
    BMC Med Genomics; 2011 Jul; 4():61. PubMed ID: 21781289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
    Antoniou A; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Loman N; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
    Am J Hum Genet; 2003 May; 72(5):1117-30. PubMed ID: 12677558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk management model for familial breast cancer: A new application using Fuzzy Cognitive Map method.
    Papageorgiou EI; Jayashree Subramanian ; Karmegam A; Papandrianos N
    Comput Methods Programs Biomed; 2015 Nov; 122(2):123-35. PubMed ID: 26220142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
    Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
    Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of CDH1 and TERT Single-Nucleotide Polymorphisms with Susceptibility to Familial Breast Cancer Risk.
    Bagherpour M; Gharibzad K; Rassi H
    Monoclon Antib Immunodiagn Immunother; 2018 Dec; 37(6):239-244. PubMed ID: 30543312
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.